Mohamed Bentires-Alj

Summary

Affiliation: Friedrich Miescher Institute
Country: Switzerland

Publications

  1. pmc Targeting protein-tyrosine phosphatases in breast cancer
    Nicola Aceto
    Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland
    Oncotarget 3:514-5. 2012
  2. pmc Parity induces differentiation and reduces Wnt/Notch signaling ratio and proliferation potential of basal stem/progenitor cells isolated from mouse mammary epithelium
    Fabienne Meier-Abt
    Mechanisms of Cancer, Friedrich Miescher Institute for Biomedical Research FMI, Maulbeerstrasse 66, Basel, CH 4058, Switzerland
    Breast Cancer Res 15:R36. 2013
  3. pmc Methods in Mammary Gland Development and Cancer: the second ENDBC meeting--intravital imaging, genomics, modeling and metastasis
    John Stingl
    Cancer Research UK, Cambridge Research Institute, Li Ka Shing Centre, UK
    Breast Cancer Res 12:311. 2010
  4. ncbi On the road to combinations of targeted therapies: PPM1H phosphatase as a suppressor of trastuzumab resistance
    Nicola Aceto
    Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland
    Cancer Discov 1:285-6. 2011
  5. pmc The devil is in the methods: lineage tracing, functional screens and sequencing, hormones, tumour-stroma interactions, and expansion of human breast tumours as xenografts
    María del Mar Vivanco
    CIC bioGUNECell Biology and Stem Cells UnitParque Tecnológico de Bizkaia, Ed 801A48160 Derio Bizkaia, Spain
    Breast Cancer Res 13:316. 2011
  6. ncbi Protein-tyrosine phosphatase 1B is required for HER2/Neu-induced breast cancer
    Mohamed Bentires-Alj
    Cancer Biology Program, Department of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Cancer Res 67:2420-4. 2007
  7. pmc It's all in the details: methods in breast development and cancer
    Mohamed Bentires-Alj
    Friedrich Miescher Institute for Biomedical Research FMI, Maulbeerstr, 66 CH 4058 Basel, Switzerland
    Breast Cancer Res 11:305. 2009
  8. doi Mammary tumor formation and metastasis evoked by a HER2 splice variant
    Abdullah Alajati
    Friedrich Miescher Institute for Biomedical Research, Maulbeerstr 66, Basel, CH 4058, Switzerland
    Cancer Res 73:5320-7. 2013
  9. doi JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer
    Adrian Britschgi
    Friedrich Miescher Institute for Biomedical Research, Basel, CH 4058, Switzerland
    Cancer Cell 22:796-811. 2012
  10. doi Protein tyrosine phosphatase 1B restrains mammary alveologenesis and secretory differentiation
    Emanuela S Milani
    Friedrich Miescher Institute for Biomedical Research, Maulbeerstr 66, 4058 Basel, Switzerland
    Development 140:117-25. 2013

Collaborators

Detail Information

Publications26

  1. pmc Targeting protein-tyrosine phosphatases in breast cancer
    Nicola Aceto
    Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland
    Oncotarget 3:514-5. 2012
    ..This approach may lead to the discovery of novel signaling mechanisms regulated by PTPs and a better understanding of cancer-associated pathways...
  2. pmc Parity induces differentiation and reduces Wnt/Notch signaling ratio and proliferation potential of basal stem/progenitor cells isolated from mouse mammary epithelium
    Fabienne Meier-Abt
    Mechanisms of Cancer, Friedrich Miescher Institute for Biomedical Research FMI, Maulbeerstrasse 66, Basel, CH 4058, Switzerland
    Breast Cancer Res 15:R36. 2013
    ..Furthermore, it opens the door to future studies assessing whether inhibitors of the Wnt pathway may be used to mimic the parity-induced protective effect against breast cancer...
  3. pmc Methods in Mammary Gland Development and Cancer: the second ENDBC meeting--intravital imaging, genomics, modeling and metastasis
    John Stingl
    Cancer Research UK, Cambridge Research Institute, Li Ka Shing Centre, UK
    Breast Cancer Res 12:311. 2010
    ..The focus was on genomics and bioinformatics, extracellular matrix and stroma-epithelial cell interactions, intravital imaging, the search for metastasis founder cells and mouse models of breast cancer...
  4. ncbi On the road to combinations of targeted therapies: PPM1H phosphatase as a suppressor of trastuzumab resistance
    Nicola Aceto
    Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland
    Cancer Discov 1:285-6. 2011
    ..This finding extends the molecular portrait of trastuzumab-resistant cells and provides a rationale when searching for potential therapeutic targets among regulators of PPM1H and/or its substrates...
  5. pmc The devil is in the methods: lineage tracing, functional screens and sequencing, hormones, tumour-stroma interactions, and expansion of human breast tumours as xenografts
    María del Mar Vivanco
    CIC bioGUNECell Biology and Stem Cells UnitParque Tecnológico de Bizkaia, Ed 801A48160 Derio Bizkaia, Spain
    Breast Cancer Res 13:316. 2011
    ..The third meeting in this series, held in April-May 2011 in Weggis, Switzerland, focussed on functional screens and sequencing, hormones, lineage tracing, tumor-stroma interactions and the expansion of human breast tumours as xenografts...
  6. ncbi Protein-tyrosine phosphatase 1B is required for HER2/Neu-induced breast cancer
    Mohamed Bentires-Alj
    Cancer Biology Program, Department of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Cancer Res 67:2420-4. 2007
    ..In contrast, PTP1B deficiency has no effect on MMTV-polyoma middle T tumorigenesis. Our data raise the possibility that PTP1B inhibitors may be chemopreventative for some forms of breast cancer...
  7. pmc It's all in the details: methods in breast development and cancer
    Mohamed Bentires-Alj
    Friedrich Miescher Institute for Biomedical Research FMI, Maulbeerstr, 66 CH 4058 Basel, Switzerland
    Breast Cancer Res 11:305. 2009
    ....
  8. doi Mammary tumor formation and metastasis evoked by a HER2 splice variant
    Abdullah Alajati
    Friedrich Miescher Institute for Biomedical Research, Maulbeerstr 66, Basel, CH 4058, Switzerland
    Cancer Res 73:5320-7. 2013
    ..Together, our results provide mechanistic insights into the activity of a highly pathogenic splice variant of HER2...
  9. doi JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer
    Adrian Britschgi
    Friedrich Miescher Institute for Biomedical Research, Basel, CH 4058, Switzerland
    Cancer Cell 22:796-811. 2012
    ..Our results provide a rationale for combined targeting of the PI3K/mTOR and JAK2/STAT5 pathways in triple-negative breast cancer, a particularly aggressive and currently incurable disease...
  10. doi Protein tyrosine phosphatase 1B restrains mammary alveologenesis and secretory differentiation
    Emanuela S Milani
    Friedrich Miescher Institute for Biomedical Research, Maulbeerstr 66, 4058 Basel, Switzerland
    Development 140:117-25. 2013
    ..Our work has implications for breast tumorigenesis because Ptp1b deletion has been shown to prevent or delay the onset of mammary tumors...
  11. pmc Calcium-activated chloride channel ANO1 promotes breast cancer progression by activating EGFR and CAMK signaling
    Adrian Britschgi
    Friedrich Miescher Institute for Biomedical Research, CH 4058 Basel, Switzerland
    Proc Natl Acad Sci U S A 110:E1026-34. 2013
    ....
  12. ncbi A role for the scaffolding adapter GAB2 in breast cancer
    Mohamed Bentires-Alj
    Cancer Biology Program, Division of Hematology Oncology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, NRB 1030, 77 Avenue Louis Pasteur, Boston, Massachusetts 02115, USA
    Nat Med 12:114-21. 2006
    ..Agents that target GAB2 or GAB2-dependent pathways may be useful for treating breast tumors that overexpress GAB2 or HER2 or both...
  13. ncbi Targeting PI3K, HER2 and the IL-8/JAK2 axis in metastatic breast cancer: Which combination makes the whole greater than the sum of its parts?
    Adrian Britschgi
    Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland
    Drug Resist Updat 16:68-72. 2013
    ....
  14. doi Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop
    Nicola Aceto
    Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland
    Nat Med 18:529-37. 2012
    ..These results provide new insights into the signaling cascades influencing tumor-initiating cells as well as a rationale for targeting SHP2 in breast cancer...
  15. ncbi Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia
    Mohamed Bentires-Alj
    Cancer Biology Program, Department of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Cancer Res 64:8816-20. 2004
    ..Our data demonstrate that mutations in PTPN11 occur at low frequency in several human cancers, especially neuroblastoma and AML, and suggest that Shp2 may be a novel target for antineoplastic therapy...
  16. pmc Epithelial protein-tyrosine phosphatase 1B contributes to the induction of mammary tumors by HER2/Neu but is not essential for tumor maintenance
    Kamal K Balavenkatraman
    Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland
    Mol Cancer Res 9:1377-84. 2011
    ..Taken together, our data show that despite the PTP1B contribution to tumor onset, it is not essential for tumor maintenance. This suggests that PTP1B inhibition could be effective in breast tumor prevention...
  17. doi Luminal expression of PIK3CA mutant H1047R in the mammary gland induces heterogeneous tumors
    Dominique S Meyer
    Friedrich Miescher Institute for Biomedical Research, Developmental and Molecular Pathways, Novartis Institutes for BioMedical Research, Basel, Switzerland
    Cancer Res 71:4344-51. 2011
    ..Our results suggest that the PIK3CA H1047R oncogene targets a multipotent progenitor cell and, furthermore, show that this model recapitulates features of human breast tumors with PIK3CA H1047R...
  18. ncbi VEGF-mediated angiogenesis links EMT-induced cancer stemness to tumor initiation
    Anna Fantozzi
    Authors Affiliations Department of Biomedicine, University of Basel and Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland
    Cancer Res 74:1566-75. 2014
    ..On the basis of these data, we propose a novel interpretation of the features of CSCs with EMT-induced, VEGF-A-mediated angiogenesis as the connecting mechanism between cancer cell stemness and tumor initiation...
  19. ncbi A tumorigenic actin mutant alters fibroblast morphology and multicellular assembly properties
    Ulrich Blache
    Focal Area Structural Biology and Biophysics, Biozentrum, University of Basel, Basel, Switzerland
    Cytoskeleton (Hoboken) 70:635-50. 2013
    ..The systematic comparison of transformed and normal spheroids by SEM provides new insights into scaffold-free fibroblast spheroid formation...
  20. pmc Can phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibition ERase them all?
    Dominique S Meyer
    Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland
    Breast Cancer Res 12:315. 2010
    ....
  21. pmc K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo
    Irmgard Hofmann
    Novartis Institutes for BioMedical Research, Oncology Disease Area, Basel, Switzerland
    PLoS ONE 7:e44146. 2012
    ..These data provide further rationale for testing combinations of MEK and PI3K inhibitors in clinical trials comprising a patient population with pancreatic cancer harboring mutations in K-RAS...
  22. ncbi Memo is a copper-dependent redox protein with an essential role in migration and metastasis
    Gwen MacDonald
    Friedrich Miescher Institute for Biomedical Research, Basel 4058, Switzerland
    Sci Signal 7:ra56. 2014
    ..Memo abundance was increased in >40% of the primary breast tumors tested, was correlated with clinical parameters of aggressive disease, and was an independent prognostic factor of early distant metastasis. ..
  23. doi How pregnancy at early age protects against breast cancer
    Fabienne Meier-Abt
    Mechanisms of Cancer, Friedrich Miescher Institute for Biomedical Research FMI, Maulbeerstrasse 66, CH 4058 Basel, Switzerland Faculty of Science, University of Basel, Klingelbergstrasse 50, CH 4056 Basel, Switzerland
    Trends Mol Med 20:143-53. 2014
    ..These new findings highlight the importance of cell-cell interactions within the mammary gland epithelium in modulating cancer risk and provide potential targets for breast cancer prevention strategies. ..
  24. doi If you don't look, you won't see: intravital multiphoton imaging of primary and metastatic breast cancer
    Laura Bonapace
    Friedrich Miescher Institute for Biomedical Research FMI, Maulbeerstrasse 66, Basel, Switzerland
    J Mammary Gland Biol Neoplasia 17:125-9. 2012
    ..We also describe a versatile multiphoton microscope for imaging tumor-stroma interactions...
  25. pmc Phosphatase-dependent and -independent functions of Shp2 in neural crest cells underlie LEOPARD syndrome pathogenesis
    Rodney A Stewart
    Dana Farber Cancer Institute, Department of Pediatric Oncology, Harvard Medical School, Boston, MA 02115, USA
    Dev Cell 18:750-62. 2010
    ....